Growth Hormone Deficiency Market Research Report Information by Brand (Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others), by Application (Pediatric Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature (ISS), Small for Gestational Age, Adult Growth Hormone Deficiency, Prader-Willi Syndrome, and Others), by Route of Administration (Subcutaneous, Intravenous, and Intramuscular), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Specialty Pharmacy), and by Region (Americas,

Growth Hormone Deficiency Market Summary

As per Market Research Future Analysis, the Growth Hormone Deficiency Market was valued at USD 4.45 Billion in 2023 and is projected to reach USD 6.42 Billion by 2032, growing at a CAGR of 3.58% from 2024 to 2032. The market is driven by advancements in diagnosis, increasing awareness, and expanding treatment options. The rising prevalence of growth hormone deficiency (GHD) and associated comorbidities such as obesity and diabetes are significant factors contributing to market growth. The pediatric segment dominated the market in 2022, while the subcutaneous route of administration led the market share. The Americas held the largest market share in 2022, attributed to developed healthcare infrastructure and technological advancements.

Key Market Trends & Highlights

The Growth Hormone Deficiency Market is witnessing notable trends and highlights.

• Market size in 2023: USD 4.45 Billion; projected to grow to USD 6.42 Billion by 2032.
• CAGR during 2024-2032: 3.58%; driven by increasing GHD prevalence and awareness.
• Pediatric growth hormone deficiency segment dominated the market in 2022.
• Subcutaneous administration route held the largest market share in 2022.

Market Size & Forecast

2023 Market Size: USD 4.45 Billion

2024 Market Size: USD 4.84 Billion

2032 Market Size: USD 6.42 Billion

CAGR (2024-2032): 3.58%

Largest Regional Market Share in 2022: Americas.

Major Players

Key companies include Novo Nordisk A/S, Pfizer, Inc., Eli Lilly and Company, Novartis AG, Hoffmann-La Roche Ltd, and Merck KGaA.

“The growth hormone deficiency market is experiencing significant growth driven by advancements in diagnosis, increasing awareness, and expanding treatment options. Growing recognition of the impact of growth hormone deficiency on health, coupled with ongoing research and development efforts, positions this market for continued expansion in the foreseeable future.”

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

The growth of the Growth Hormone Deficiency Market is expected to be driven by the increasing number of individuals suffering from growth hormone deficiency (GHD), rising awareness regarding the effectiveness of GH along with clinical trials focused on the safety and efficacy of GHD, and the changing lifestyle along with the growing prevalence of genetic disorders.

Growth Hormone Deficiency Trends

Increasing prevalence of growth hormone deficiency fuels market growth

According to the published article in NCBI in March 2017, the estimated prevalence of GHD is approximately 2-3 in 10,000 population. GHD is caused by structural pituitary disease or cranial irradiation and occurs in the context of additional features of hypopituitarism. Pituitary adenomas are reported to cause adult-onset GHD followed by craniopharyngiomas, which accounts for approximately 57% of cases. In addition, childhood-onset growth hormone deficiency (CO-GHD) is one of the complex endocrine conditions that may have an impact throughout life, starting in childhood, and continuing till adulthood. Most of the CO-GH is reported to be congenital. The main co-morbidities and symptoms of GHD in adults and children are obesity, diabetes mellitus, hypertension, cerebrovascular diseases, cardiovascular diseases, and liver diseases. This increasing morbidity of GH disease in both children and adults is expected to drive the growth of the growth hormone deficiency market. 

Growth Hormone Deficiency Segment Insights

Growth Hormone Deficiency Brand Insights

The Growth Hormone Deficiency Market segmentation, based on brand, includes Norditropin, Genotropin, Humatrope, Saizen, Omnitrope, and others. The others segment held the majority share in the market in 2022. Others include Nutropin, Jintropin, Growject, Hormotrop, Tev-tropin, Nutropinaq, Zomacton, and Eutropin.

Growth Hormone Deficiency Application Insights

The Growth Hormone Deficiency Market segmentation, based on application, includes paediatric growth hormone deficiency, idiopathic short stature, small for gestational age, turner syndrome, adult growth hormone deficiency, prader-willi syndrome, and others. The paediatric growth hormone deficiency segment dominated the market in 2022. Growth hormone deficiency is a rare condition that affects less than one in 3,000 to one in 10,000 children in the US, according to the American Academy of Paediatrics.

Figure 2: Growth Hormone Deficiency Market, by Application, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Growth Hormone Deficiency Route of Administration Insights

The Growth Hormone Deficiency Market segmentation, based on route of administration, subcutaneous, intramuscular, and intravenous. The subcutaneous segment dominated the market in 2022. The segment growth is increasing as it leads to a significant rise in growth rates in patients and a low incidence of antibody development. The majority of the GHD drugs are administered through subcutaneous ROA (Route of Administration). For instance, brands such as Norditropin, Genotropin, Humatrope, Omnitrope, Nutropin, and Saizen are administered subcutaneously.

Growth Hormone Deficiency Distribution Channel Insights

The Growth Hormone Deficiency Market segmentation, based on distribution channel, includes hospital pharmacies, retail pharmacies, clinics, and e-commerce websites. The hospital pharmacies segment dominated the market in 2022. Recombinant growth hormone is a prescription medication made available only with a prescription of a physician. Moreover, most hospitals have a policy that patients ought to buy medications prescribed by the practitioners from their premises only. Additionally, high investments by governments for the development of advanced healthcare centers and hospitals in various countries are also contributing to the distribution of growth hormone medicines through hospital pharmacies.

Growth Hormone Deficiency Regional Insights

By Region, the study segments the market into Americas, Europe, Asia-Pacific, and Middle East & Africa. The Americas growth hormone deficiency market accounted for the largest market share in 2022. Key factors attributed to its large share include developed healthcare infrastructure, increasing technological advancement, and the presence of many market players in the region.

Further, the major countries will be study are US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: GROWTH HORMONE DEFICIENCY MARKET BY REGION 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe growth hormone deficiency market accounted for the second-largest market share due to growing prevalence of GHD individuals, and the rising awareness of treatment. Furthermore, the Germany growth hormone deficiency market is attributed to hold the largest market share, and the France growth hormone deficiency market is projected be the fastest growing market in the Europe region.

The Asia-Pacific growth hormone deficiency market is expected to be the fastest growing from 2023 to 2032 due to growing advancement in treatment, increasing funds in research activities, and rising prevalence of GHD. Moreover, China growth hormone deficiency market accounted to hold the largest market share, and the India growth hormone deficiency market is projected to be the fastest growing market in the Asia-Pacific region.

Growth Hormone Deficiency Key Market Players & Competitive Insights

The Growth Hormone Deficiency Market is characterized by many global, regional, and local vendors catering to the demand created by a large patient pool suffering from growth hormone deficiency. The market is highly competitive, with players competing and collaborating to gain a substantial market share in the Growth Hormone Deficiency Market. Expansion into newer untapped markets, novel product launches, rising collaborative agreements, and decisions undertaken to achieve operational efficiency are key factors that aid market growth. Our analysis revealed that market players had adopted different strategies and innovative research & development techniques to expand their business and secure their position in the Growth Hormone Deficiency Market. In recent years, strategic collaborations by major players for product development and regional expansion into untapped markets have been used as a strategy to obtain operational efficiency.

Merck KGaA (Merck) is a leading pharmaceutical company that offers several products sub grouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and provides breakthrough solutions and technologies. It has expanded its global footprint through several mergers & acquisitions, such as the acquisition of Millipore and Sigma. EMD Sereno, Inc. is a biopharmaceutical business of Merck that is engaged in developing the Somatropin injection. It works with clients and in more than 140 countries to provide innovative healthcare products globally.

Key Companies in the Growth Hormone Deficiency market includes

• Novo Nordisk A/S (Denmark)
• Pfizer, Inc. (US)
• Eli Lily and Company (Netherlands)
• Novartis AG (Switzerland)
• Hoffmann-La Roche Ltd (Switzerland)
• Novartis AG (Switzerland)
• Ispen Pharma (Switzerland)
• Ferring Pharmaceuticals (Switzerland)
• Merck KGaA (Germany)
• AnkeBio Co., Ltd (China)
• Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China)

Growth Hormone Deficiency Industry Developments

• Q2 2024: FDA Approves Sogroya (somapacitan-beco) for Pediatric Growth Hormone Deficiency The FDA approved Novo Nordisk's Sogroya, a once-weekly growth hormone therapy, for use in children with growth hormone deficiency, expanding its previous adult indication.
• Q1 2024: Novo Nordisk Announces Launch of Sogroya for Pediatric Use in the United States Novo Nordisk launched Sogroya (somapacitan-beco) for pediatric patients with growth hormone deficiency in the U.S., following FDA approval, marking the first once-weekly treatment option for children.
• Q2 2024: Pfizer and OPKO Health Receive European Commission Approval for NGENLA in Pediatric Growth Hormone Deficiency The European Commission approved NGENLA (somatrogon), a long-acting growth hormone therapy developed by Pfizer and OPKO Health, for pediatric patients with growth hormone deficiency.
• Q2 2024: Pfizer Launches NGENLA in Key European Markets for Pediatric Growth Hormone Deficiency Pfizer announced the commercial launch of NGENLA, a once-weekly growth hormone injection, in several European countries for the treatment of pediatric growth hormone deficiency.
• Q3 2024: FDA Accepts IND Application for LUM-201 in Pediatric Growth Hormone Deficiency The FDA accepted Lumos Pharma's Investigational New Drug (IND) application for LUM-201, an oral growth hormone secretagogue, for the treatment of pediatric growth hormone deficiency, enabling Phase 3 clinical trials.
• Q1 2025: Lumos Pharma Announces First Patient Dosed in Phase 3 Trial of LUM-201 for Pediatric Growth Hormone Deficiency Lumos Pharma began dosing patients in its pivotal Phase 3 clinical trial evaluating LUM-201, an oral therapy for pediatric growth hormone deficiency.
• Q2 2025: Ascendis Pharma Receives FDA Approval for SKYTROFA Auto-Injector Device Ascendis Pharma received FDA approval for its new auto-injector device for SKYTROFA (lonapegsomatropin-tcgd), a once-weekly growth hormone therapy, improving administration for pediatric patients.
• Q2 2024: Ascendis Pharma Launches SKYTROFA in Japan for Pediatric Growth Hormone Deficiency Ascendis Pharma announced the commercial launch of SKYTROFA, a long-acting growth hormone therapy, in Japan for pediatric patients with growth hormone deficiency.
• Q3 2024: OPKO Health and Pfizer Expand NGENLA Distribution Agreement in Latin America OPKO Health and Pfizer expanded their distribution agreement for NGENLA, a long-acting growth hormone therapy, to include additional Latin American countries.
• Q1 2025: Genexine and Handok Announce Partnership to Develop and Commercialize GX-H9 in Southeast Asia Genexine and Handok entered a partnership to co-develop and commercialize GX-H9, a long-acting growth hormone candidate, for growth hormone deficiency in Southeast Asian markets.
• Q2 2025: Novo Nordisk Opens New Manufacturing Facility for Growth Hormone Therapies in Denmark Novo Nordisk inaugurated a new manufacturing facility in Denmark dedicated to the production of growth hormone therapies, aiming to meet rising global demand.
• Q2 2025: Pfizer Appoints New Head of Rare Disease Division to Oversee Growth Hormone Deficiency Portfolio Pfizer appointed a new executive to lead its Rare Disease Division, with oversight of the company’s growth hormone deficiency product portfolio, including NGENLA.

Growth Hormone Deficiency Segmentation

Growth Hormone Deficiency Brand Outlook

• Norditropin
• Genotropin
• Humatrope
• Saizen
• Omnitrope
• Others

Growth Hormone Deficiency Application Outlook

• Paediatric Growth Hormone Deficiency
• Idiopathic Short Stature
• Small for Gestational Age
• Turner Syndrome
• Adult Growth Hormone Deficiency
• Prader-Willi Syndrome
• Others

Growth Hormone Deficiency Route of Administration Outlook

• Subcutaneous
• Intramuscular
• Intravenous

Growth Hormone Deficiency Distribution Channel Outlook

• Hospital Pharmacies
• Retail Pharmacies
• Clinics
• E-Commerce Websites

Growth Hormone Deficiency Regional Outlook

• Americas
  • North America
    • US
    • Canada
    • Latin America
• Europe
  • Western Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Western Europe
• Eastern Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Middle East & Africa
  • Middle East
  • Africa
  • Latin America

Report Attribute/Metric	Details
Market Size 2023	USD 4.45 Billion
Market Size 2024	USD 4.84 Billion
Market Size 2032	USD 6.42 Billion
Compound Annual Growth Rate (CAGR)	3.58% (2024-2032)
Base Year	2023
Forecast Period	2024-2032
Historical Data	2019 to 2022
Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered	Brand, Application, Route of Administration, Distribution Channel, and Region
Geographies Covered	North America, Europe, Asia Pacific, and Rest of the World
Countries Covered	The US, Canada, Germany, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Novo Nordisk A/S (Denmark), Pfizer, Inc. (US), Merck KGaA (Germany), Eli Lily and Company (Netherlands), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland), Novartis AG (Switzerland), Ispen Pharma (Switzerland), Ferring Pharmaceuticals (Switzerland), AnkeBio Co., Ltd (China), and Zhongshan Sinobioway Hygene Biomedicine Co., Ltd (China)
Key Market Opportunities	·       Strong pipeline of hormonal drugs·       Easy availability of pharma drugs on E-commerce platforms
Key Market Drivers	·       Increasing cost of GHD·       Increasing counterfeit products for GHD treatment·       Rising number of strategic initiatives